Once approved, Decapeptyl® 6-month formulation will be marketed by Debiopharm’s partners, such as Ipsen in most European Union countries. “This submission in Europe of our first 6-month-formulation ...
This is a preview. Log in through your library . Abstract The effects of depot formulations of the luteinizing hormone-releasing hormone (LHRH) agonist Decapeptyl (25 µg/day) for 30 days or LHRH ...
PARIS, Feb 7 (Reuters) - Ipsen said a late-stage study of its Decapeptyl drug when injected into patients with locally advanced or metastatic prostate cancer was positive. The results matched the ...
Debiopharm (Debiopharm – www.debiopharm.com) and Ipsen (www.ipsen.com) today announced renewal of their Decapeptyl ® agreement, which extends and strengthens their strategic partnership through 2034 ...
in-licenses know-how and new patent applications for the commercialization rights of Decapeptyl(R) (triptorelin pamoate) in the world excluding North America, and some other countries (Sweden, Israel, ...
Debiopharm and Ipsen extend and strengthen their ongoing collaboration to ensure patient access to Decapeptyl for the treatment of certain urological, gynecological and pediatric conditions Regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback